Flow-mediated dilation benefits of mesoglycan in peripheral artery disease

International Angiology

Volumn 34, Issue 4, 2015, Pages 398-406

  Gossetti, B ^a,b   Antignani, P L ^a,b   Jabbour, J ^a,b   Martinelli, O ^a,b  

^a POLICLINICO UMBERTO I   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Mesoglycan; Peripheral arterial disease; Walking

Indexed keywords

MESOGLYCAN; GLYCOSAMINOGLYCAN;

ADD ON THERAPY; ADULT; AGED; AGING; ARTERIAL WALL THICKNESS; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; WALKING; CAROTID ARTERY; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRACHIAL ARTERY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 84946919784     PISSN: 03929590     EISSN: 18271839     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Brevetti G, Oliva G, Silvestro A, Scopacasa F, Chiariello M. Peripheral Arteriopathy and Cardiovascular Events (PACE) Study Group. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial diseaseinltaly. Atherosclerosis 2004;175:131-8.
2. Sanna G, Alesso D, Mediati M, Cimminiello C, Borghi C, Fazzari AL et al. PANDORA study investigators. Prevalence of peripheral arterial disease in subjects with moderate cardiovascular risk: Italian results from the PANDORA study Data from PANDORA (Prevalence of peripheral Arterial disease in subjects N with moderate CVD risk, with No overt vascular Diseases nor Diabetes mellitus). BMC CardiovascDisord 2011;11:59.
3. Vita JA, Hamburg NM. Does endothelial dysfunction contribute to the clinical status of patients with peripheral arterial disease? Can J Cardiol 2010;26(Suppl A):45A-50A.
4. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb 2013;20:1-8.
5. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300:H2-12.
6. Toda N. Age-related changes in endothelial function and blood flow regulation. Pharmacol Ther 2012;133:159-76.
7. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74.
8. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010;26:631-40.
9. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011;18:775-89.
10. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000;440:653-66.
11. Koo A, Dewey CF Jr, García-Cardeña G. Hemodynamic shear stress characteristic of atherosclerosis-resistant regions promotes glycocalyx formation in cultured endothelial cells. Am J Physiol Cell Physiol 2013;304:C137-46.
12. Giantsos-Adams KM, Koo AJ, Song S, Sakai J, Sankaran J, Shin JH et al. Heparan sulfate regrowth profiles under laminar shear flow following enzymatic degradation. Cell MolBioeng 2013;6:160-74.
13. Fu BM, Tarbell JM. Mechano-sensing and transduction by endothelial surface glycocalyx: composition, structure, and function. Wiley Interdiscip Rev Syst Biol Med 2013;5:381-90.
14. Tarbell JM, Ebong EE. The endothelial glycocalyx: a mechano-sensor and -transducer. Sci Signal 2008;1:pt8.
15. Drake-Holland AJ, Noble MI. Update on the important new drug target in cardiovascular medicine - the vascular glycocalyx. Cardiovasc Hematol Disord Drug Targets 2012;12:76-81.
16. Bai K, Wang W. Shear stress-induced redistribution of the glycocalyx on endothelial cells in vitro. Biomech Model Mechanobiol 2014;13:303-11.
17. Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res 2003;93:e136-42.
18. Tanganelli P, Bianciardi G, Carducci A, Palummo N, Simoes C, Tarabochia B et al. Updating on in-vivo and invitro effects of heparin and other glycosaminoglycans (mesoglycan) on arterial endothelium: a morphometrical study. Int J Tissue React 1992;14:149-53.
19. Tesi M, Bronchi GF, Carini A, Karavassili M. Therapy of atherosclerotic arteriopathy of lower limbs. Aspects and results. Angiology 1985;36:720-35.
20. Scolari EA. Mesoglycan in the treatment of chronic obstructive arteriopathies of the legs. Clin Ter 1988;126:43-7.
21. Di Giovanna VN. Treatment with mesoglycan of chronic obliterative atherosclerotic arteriopathies of the legs. Hematochemical and flowmetric changes. Clin Ter 1988;125:431-4.
22. Strano A, Pinto A, Galati D. Double-blind controlled study of the efficacy and pharmacological properties of heparan sulfate in patients with occlusive arterial disease of the lower limbs. Drugs Exp Clin Res 1990;16:543-50.
23. Auteri A, Celaco G, Gasparro MG, Verzuri MS, Artale F et al. Glycosaminoglycans for the treatment of peripheral arterial diseases. Multicenter study. Giorn It Angiol 1991;9:24-30.
24. Raso AM, Maggio D, Trogolo M, Rispoli P, Sandrone N, Pezzuto D et al. Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol. Minerva Cardioangiol 1997;45:383-92.
25. Nenci GG, Gresele P, Ferrari G, Santoro L, Gianese F. Mesoglycan Intermittent Claudication Group. Treatment of intermittent claudication with mesoglycan-a placebo-controlled, double-blind study. Thromb Haemost 2001;86:1181-7.
26. Stoner L, Sabatier MJ. Use of ultrasound for non-invasive assessment of flow-mediated dilation. J Atheroscler Thromb 2012;19:407-21.
27. Dyson KS, Argarwal N, Williams-Bell M, Bhatti A, Denniss SG, Hughson RL. Sustained hyperaemia stimulus is necessary to induce flow-mediated dilation ofthe human brachial artery. Clin Physiol Funct Imaging 2011;31:415-21.
28. Liuni A, Luca MC, Lisi M, Dragoni S, Di Stolfo G, Mariani JA et al. Observations of time-based measures of flowmediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. Am J Physiol Heart Circ Physiol 2010;299:H939-45.
29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
30. Maldonado FJ, Miralles Jde H, Aguilar EM, Gonzalez AF, Garcia JR, Garcia FA. Relationship between noninvasively measured endothelial function and peripheral arterial disease. Angiology 2009-2010;60:725-31.
31. Yataco AR, Corretti MC, Gardner AW, Womack CJ, Katzel LI. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol 1999;83:754-8.
32. Yu HI, Sheu WH, Lai CJ, Lee WJ, Chen YT. Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. Int J Cardiol 2001;78:19-25.
33. Silvestro A, Scopacasa F, Ruocco A, Oliva G, Schiano V, Zincarelli C et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 2003;8:225-32.
34. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO et al. Predictive value of noninvasively determined endothelial dysfunction for longterm cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-75.
35. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003;108:2093-8.
36. Santos-García D, Rodríguez-Yáñez M, Arias-Rivas S, Blanco M. Brachial arterial flow mediated dilation: utility in clinical and experimental practice. Rev Neurol 2011;53:351-60.
37. Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis 2011;214:129-38.
38. Kotb NA, Gaber R, Salah W, Elhendy A. Relations among glycemic control, circulating endothelial cells, nitric oxide, and flow mediated dilation in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012;120:460-5.
39. Toda N, Toda H. Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine. Eur J Pharmacol 2010;649:1-13.
40. Hamburg NM, Palmisano J, Larson MG, Sullivan LM, Lehman BT, Vasan RS et al. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension 2011;57:390-6.
41. Pacella E, Pacella F, Turchetti P, Mazzeo F, Anzi Dei R, Malvasi A et al. A pilot clinical study on the effectiveness of mesoglycan against diabetic retinopathy. Clin Ter 2012;163:19-22.
42. Lauer T, Heiss C, Preik M, Balzer J, Hafner D, Strauer BE et al. Reduction of peripheral flow reserve impairs endothelial function in conduit arteries of patients with essential hypertension. J Hypertens 2005;23:563-9.
43. Gossetti B, Felli M, Castiglione A, Alunno A, Jabbour J, Santoro L and Italian Mesoglican Group. Mesoglycan in patients with chronic obstructive arterial diseases of lower limbs: effect on walking distance, intimal-media thickness and brachial flow mediated dilation. Minerva Cardioangiol 2008;56:162-5.
44. Allegra C, Antignani PL. Assessing mesoglycan treatment efficacy in 1483 outpatients with chronic venous insufficiency Minerva Cardioangiol 2011;59(2, Suppl. 1):1-7.